Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?-Reference-Cited by-同舟云学术

Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?

Published:2011-02-10 Issue:6 Volume:117 Page:2009-2011
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Avet-Loiseau Hervé¹,Malard Florent¹,Campion Loic²,Magrangeas Florence¹,Sebban Catherine³,Lioure Bruno⁴,Decaux Olivier⁵,Lamy Thierry⁶,Legros Laurence⁷,Fuzibet Jean-Gabriel⁸,Michallet Mauricette⁹,Corront Bernadette¹⁰,Lenain Pascal¹¹,Hulin Cyrille¹²,Mathiot Claire¹³,Attal Michel¹⁴,Facon Thierry¹⁵,Harousseau Jean-Luc¹⁶,Minvielle Stephane¹,Moreau Philippe¹⁷,

Affiliation:

1. Hematology Laboratory, University Hospital, and Inserm U892, Nantes, France;

2. Department of Statistics, Centre René Gauducheau, Nantes, France;

3. Hematology Department, Centre Léon Bérard, Lyon, France;

4. Hematology Department, University Hospital, Strasbourg, France;

5. Internal Medicine Department, University Hospital, Rennes, France;

6. Hematology Department, University Hospital, Rennes, France;

7. Hematology Department, University Hospital, Nice, France;

8. Internal Medicine Department, University Hospital, Nice, France;

9. Hematology Department, University Hospital, Lyon, France;

10. Hematology Department, University Hospital, Annecy, France;

11. Hematology Department, Centre François Baclesse, Rouen, France;

12. Hematology Department, University Hospital, Nancy, France;

13. Hematology Laboratory, Institut Curie, Paris, France;

14. Hematology Department, University Hospital, Toulouse, France;

15. Hematology Department, University Hospital, Lille, France;

16. Hematology Department, Centre René Gauducheau, Nantes, France; and

17. Hematology Department, University Hospital, Nantes, France

Abstract

Abstract Many trials in myeloma are stratified on cytogenetic abnormalities. Among them, the most commonly chosen are the t(4;14), the del(17p), and the t(14;16). If data are well established for t(4;14) and del(17p), very few data support the use of t(14;16). To address this issue, we retrospectively analyzed 1003 patients with newly diagnosed myeloma for this abnormality. We identified 32 patients with the t(14;16). Compared with patients lacking the t(14;16), we did not observe any difference in overall survival (P = .28). Moreover, in multivariate analyses, the t(14;16) was not prognostic (P = .39). In conclusion, our data do not support the use of t(14;16)-specific probes in the diagnostic panels of multiple myeloma.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/117/6/2009/1341356/zh800611002009.pdf

Reference10 articles.

1. Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma.;Chesi;Blood,1998

2. Ectopic expression of MAFB gene in human myeloma cells carrying the t(14;20)(q32;q11) chromosomal translocations.;Hanamura;Jpn J Cancer Res,2001

3. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma.;Hurt;Cancer Cell,2004

4. Clinical and biologic implications of recurrent genomic aberrations in myeloma.;Fonseca;Blood,2003

5. Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance.;Nair;Blood,2010

Cited by 111 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Still high risk? A review of translocation t(14;16) in multiple myeloma;American Journal of Hematology;2024-06-14

2. A rare case of IgA lambda multiple myeloma in a 32-year-old woman with t(14;16) translocation associated with kidney injury and non-albumin proteinuria;BMC Nephrology;2024-05-16

3. High‐risk multiple myeloma: Redefining genetic, clinical, and functional high‐risk disease in the era of molecular medicine and immunotherapy;American Journal of Hematology;2024-04-13

4. Molecular Pathogenesis of Multiple Myeloma;Hematology/Oncology Clinics of North America;2024-04

5. MAF translocation remains a strong prognostic factor despite concurrent chromosomal abnormalities;Haematologica;2024-01-18